Search Medical Condition
Please enter condition
Please choose location from dropdown

Zhenzhou, China Clinical Trials

A listing of Zhenzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (189) clinical trials

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women

To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.

Phase

0.0 miles

Learn More »

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

STUDY BACKGROUND Breast cancer is a serious disease that threatens human health and life. Especially in China, the incidence rate is increasing year by year. According to WHO data, the incidence of breast cancer in China in 2020 will reach 214,000. Selective estrogen receptor modulators (SERMs) are a classic form ...

Phase

0.0 miles

Learn More »

Site Selection of Short Peripheral Venous Catheters

Up to 90% of catheters fail before therapy is complete. Improved dwell time of intravenous catheters for even small increments of time would further reduce the number of insertions, staff workloads, and costs. In this study, the investigators investigated whether short peripheral venous catheter site of insertion influence the dwell ...

Phase N/A

0.0 miles

Learn More »

Tirofiban for Patients Treated With Alteplase

After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone.

Phase

0.0 miles

Learn More »

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Participants considered an adult according to local regulations at the time of signing informed consent will be randomized in a 1:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will enter the screening period up to 14 days prior to the start of treatment. Prior to randomization, the investigator will ...

Phase

0.0 miles

Learn More »

Incidence of Pancreatic Fistula After Radical Gastrectomy

Pancreatic fistula, which can lead to fatal end, is one of the most serious complications after radical gastrectomy. It is usually treated as a key factor to evaluate the quality of gastrectomy. The incidence of pancreatic fistula is far different between different areas, knowing the prevalence of pancreatic fistula and ...

Phase N/A

0.0 miles

Learn More »

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with blast excess

Phase

0.0 miles

Learn More »

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstr m's Macroglobulinemia (WM)

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff for final analysis.

Phase

0.0 miles

Learn More »

The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.

This is a randomized, controlled study. This study will be performed at Aarhus University Hospital (Denmark), Ghent University Hospital (Belgium) and Hospital of Zhengzhou University (China) following the same protocol. According to the initial randomization, children will be allocated to treatment without (group A) or with (group B) prior clinical ...

Phase

0.0 miles

Learn More »

Study of BCMA CAR-T in Multiple Myeloma

The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed ...

Phase

0.0 miles

Learn More »